Asthma
Is Ventolin Being Phased Out in the UK? What Patients Need to Know
Many people in the UK have noticed changes to their asthma prescriptions, particularly involving Ventolin and other blue reliever inhalers, leading to concerns that these medicines are being phased out completely.
While salbutamol inhalers such as Ventolin still play an important role in asthma management, the National Health Service (NHS) and the National Institute for Health and Care Excellence (NICE) are encouraging safer and more sustainable treatment approaches, including MART combination inhalers and lower-carbon alternatives like Salamol.
This article explains why repeat prescriptions are changing, whether blue inhalers are disappearing and what UK patients should expect when managing their asthma through providers such as Mail My Meds.
In One Sentence:
Ventolin is not being banned in the UK, but many patients are being moved towards safer and more environmentally friendly asthma treatments as part of modern asthma management guidance.
Key Takeaways
Are blue inhalers being banned?
Blue inhalers are not being banned, but NHS guidance is reducing reliance on Salbutamol inhalers and short-acting beta-agonist (SABA) monotherapy due to risks linked with poor lung health.
Are prescriptions changing?
Many patients are seeing prescription changes because GP practices are reviewing repeat prescriptions and encouraging better long-term asthma control.
Will medications be switched?
Some patients are being switched from Ventolin Evohaler to Salamol as part of a brand swap linked to high-carbon propellants and NHS sustainability goals.
What alternatives are being offered?
A Dry Powder Inhaler (DPI) or combination MART inhaler may be offered as an alternative, depending on asthma severity and inhaler suitability.
Do patients need to change how they use their medication immediately?
Patients should continue using their inhalers as prescribed and speak to their GP, nurse or pharmacist before making any treatment changes.
Why is your GP changing your blue inhaler prescription?
Many GP surgeries are changing asthma prescriptions because frequent use of short-acting beta-agonists (SABAs) can indicate poorly controlled asthma and increased risk of severe attacks.
Blue inhalers such as Ventolin are designed to provide quick relief from breathlessness by relaxing airway muscles, but they do not treat the underlying lung inflammation or airway swelling that causes asthma symptoms. These relievers can temporarily reduce symptoms while masking worsening asthma control, which may delay patients from seeking appropriate preventative medication.
NICE Guidance
NICE guidance increasingly focuses on reducing overreliance on blue inhalers and encouraging the use of Inhaled Corticosteroids (ICS) to control inflammation. Patients who repeatedly request blue inhalers, especially through automatic monthly repeat lists, may be invited for an annual asthma review to assess whether their asthma management plan remains suitable.
European Respiratory Journal
Research published in the European Respiratory Journal found that overuse of short-acting beta-agonists (SABAs) was associated with increased risks of severe asthma attacks, hospital admissions and asthma-related death. The study highlighted that patients using multiple reliever inhalers each year were more likely to experience uncontrolled asthma symptoms and poorer long-term outcomes [1].
This is why many GP and general practitioner teams now review how often patients request blue inhalers. Rather than simply issuing repeated prescriptions, healthcare professionals may recommend preventative medication or combination inhalers that address airway swelling and inflammation more effectively.
Ventolin vs Salamol: How does the green inhaler swap work?
The green inhaler swap involves moving some patients from Ventolin Evohaler to lower-carbon inhaler options such as Salamol CFC-Free or Dry Powder Inhalers (DPIs).
Both Ventolin Evohaler and Salamol contain the same active drug, salbutamol (100 micrograms), which works by relaxing airway muscles to ease breathing symptoms. For most patients, the medication itself works in a very similar way. However, the devices use different formulations and propellant systems.
Feature | Ventolin Evohaler | Salamol CFC-Free | |||
| Active Ingredient | Salbutamol (100 micrograms) | Salbutamol (100 micrograms) | |||
| Medical Efficacy | Fast-acting airway muscle relaxation | Identical fast-acting relief | |||
| Propellant Volume | High HFA volume | Low HFA volume | |||
| Carbon Impact | Approx. 28kg CO2 equivalent per inhaler | Approx. 11kg CO2 equivalent per inhaler |
Hydrofluoroalkane (HFA) Propellants
One major reason for the NHS green inhaler swap is the environmental impact of hydrofluoroalkane (HFA) propellants used in many traditional inhalers.
These propellants contribute to greenhouse gas emissions and have a significant CO2 equivalent impact compared with Dry Powder Inhalers (DPIs), which do not use propellant gases.
Research published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery examined the environmental impact of inhalers and highlighted the importance of reducing carbon emissions linked with hydrofluoroalkane (HFA) propellants as healthcare systems work towards sustainability targets [2].
As part of wider NHS environmental health and sustainability goals, some patients are therefore being moved towards lower-emission devices. Salamol is often considered during this process because its inhaler design has a lower carbon footprint than some older salbutamol inhalers. Dry Powder Inhalers (DPIs) may also be recommended as a near-zero-emission alternative where clinically appropriate.
“Patients should remember that a green inhaler swap does not mean their asthma is worsening. In most cases, the NHS is balancing effective asthma treatment with efforts to reduce carbon emissions across healthcare services.”
What are the new style inhalers? (MART Therapy)
MART therapy uses a combination inhaler that acts as both a daily preventer and a reliever treatment.
MART, which stands for Maintenance and Reliever Therapy, is becoming more widely used by respiratory specialists because it treats both immediate symptoms and underlying airway swelling at the same time. Instead of relying heavily on a separate blue inhaler, patients use one combination inhaler containing both a steroid preventer and a fast-acting reliever medicine.
This dual-action method means patients receive anti-inflammatory treatment every time they take a reliever puff. That helps reduce inflammation, improve symptom control and lower the risk of exacerbations and emergency oral steroids.
Traditional asthma treatment often involved a brown inhaler for prevention and a blue inhaler for symptom relief. However, MART therapy combines these approaches into one device using carefully balanced micro-dose treatment throughout the day.
Clinical trials demonstrate that MART significantly reduced severe asthma attacks and improved overall asthma control compared with traditional reliever-based treatment approaches [3].
Patients with frequent tight chest symptoms, repeated blue inhaler use or uncontrolled inflammation may therefore benefit from switching to a combination MART inhaler. These newer treatment plans are increasingly supported by NICE recommendations because they can improve long-term asthma outcomes while reducing dependence on short-acting relievers.
Not every patient will be suitable for MART therapy, and some people may still require separate rescue medication. A GP, asthma nurse or pharmacist can assess whether this treatment approach is appropriate based on symptoms, inhaler technique and overall asthma severity.
Treatment Approach | Inhaler Setup | How It Works | Primary Clinical Benefit | ||||
| Traditional Method | Two separate inhalers (Blue reliever and Brown preventer) | The patient takes a daily preventer, then uses the blue inhaler only during sudden flare-ups. | Standardised care, but it heavily relies on the patient remembering their daily preventative dose. | ||||
| MART Therapy | One single combination inhaler | The patient uses the same device for daily maintenance and emergency symptom relief. | Delivers a micro-dose of anti-inflammatory steroid at the exact moment of an attack, treating the root cause. |
Summary: What should UK asthma patients do next?
UK asthma patients should review their current treatment plan with their GP or pharmacy team to ensure their inhalers remain safe, effective and appropriate.
Repeat Prescriptions
If your repeat prescription list has changed, it is important not to panic or stop taking medication without medical advice. Many brand switch decisions involving Salamol or Ventolin are routine updates linked to environmental health goals, prescribing guidance and asthma safety reviews.
Emergency Medication
Patients who use rescue medication frequently may benefit from an asthma review to check whether their symptoms are fully controlled. This review may involve assessing breathing technique, checking inhaler adherence and considering whether a combination MART inhaler or dry powder inhaler would provide better symptom control.
Your GP, practice nurse or pharmacy team may also review how often you request emergency reliever medication. Frequent use of blue inhalers can sometimes indicate uncontrolled asthma, even if symptoms feel manageable day to day.
“Patients should continue attending annual asthma reviews and ask questions if they are unsure about any brand switch or inhaler change. Asthma treatment is becoming more personalised, with increasing focus on prevention, lung protection and reducing environmental impact across the UK healthcare system.”
Frequently Asked Questions
Is Salamol the same as Ventolin?
Salamol and Ventolin both contain 100 micrograms of salbutamol per puff to help relax the lungs and airways during asthma symptoms.
Although the medication inside each canister is very similar, the inhaler devices and propellant gas systems can feel slightly different when used. Both inhalers are designed to treat breathlessness and reduce symptoms during an asthma attack by delivering salbutamol directly into the lungs.
Some patients notice small differences in taste, spray force, or inhaler feel, but the active medicine itself remains the same.
Why has my blue inhaler been removed from my repeat prescription?
Blue inhalers are sometimes removed from automatic repeat prescriptions because dangerous overuse can suggest uncontrolled asthma.
GP practices increasingly review salbutamol inhaler requests rather than issuing repeated prescriptions automatically. If a patient requests frequent blue inhalers, healthcare professionals may recommend a medical review to check whether preventative medication would provide safer long-term control.
Removing automatic repeats can help identify patients whose asthma symptoms may be worsening without proper treatment adjustment.
Can I still request Ventolin if I prefer it?
Some patients can still request Ventolin, but NHS practices may encourage eco-friendly options where suitable.
A doctor or asthma specialist may continue prescribing Ventolin if there is a medical intolerance or difficulty using the Salamol device. However, many NHS practices now support the green inhaler swap by recommending lower-carbon alternatives when clinically appropriate.
Patients should discuss any concerns openly with their GP, nurse or pharmacist before changing inhalers.
Final Thoughts From Our Superintendent Pharmacist
“Short-acting relievers such as Ventolin still have an important place in asthma care, but modern asthma treatment is moving towards better long-term control through MART therapy, preventative treatment and improved inhaler technique. Patients should attend annual asthma reviews regularly and speak with healthcare professionals if they notice increasing inhaler use or worsening symptoms. Low-carbon alternatives can support environmental protection while still maintaining effective asthma treatment when prescribed appropriately.”
Sources
[2] Carbon footprint impact of the choice of inhalers for asthma and COPD - PubMed
About the author
Blog author
Rachael Clarke
